Navigation Links
BioLife Solutions to Supply CryoStor(TM) to Cryobanks International as Standard Media for Preservation and Storage of Umbilical Cord Blood Stem Cells

Cord Blood Bank Sees Significant Benefits from Next-Generation

Biopreservative Product

BOTHELL, Wash., Nov. 4 /PRNewswire-FirstCall/ -- BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading developer and marketer of proprietary hypothermic storage and cryopreservation media products for cells, tissues, and organs, today announced that it will supply its CryoStor biopreservative freezing media to Cryobanks International, a Florida-based cord blood stem cell bank for private and public-donation purposes, for long-term storage of stem cells isolated from umbilical cord blood.

Umbilical cord blood, which is typically discarded after birth, is a rich source of stem cells that have been transfused in thousands of patients to cure numerous fatal diseases including leukemia, lymphoma, anemia, and myelofibrosis.

Cryobanks Chief Operating Officer Robert Gravely stated: "We are an AABB (formerly American Association of Blood Banks) accredited participating member of the National Marrow Donor Program and currently have more than ten thousand cord blood units available for unrelated recipients.

"We strive to continually improve the quality and effectiveness of our biopreservation systems," Gravely continued, "and BioLife's scientific data indicated that the use of pre-formulated CryoStor as the freezing media resulted in improved post-preservation stem cell viability and function. After conducting further evaluations of CryoStor, we decided to replace our internally formulated media with CryoStor, which is produced under current Good Manufacturing Practices (cGMP) and supported by a Master File with the U.S. Food and Drug Administration (FDA)."

Donald Hudspeth, Cryobanks general manager, described the results of Cryobanks' technical evaluation of CryoStor: "As compared to our previous internally mixed Dextran/DMSO/saline preservation media, CryoStor improved total nucleated cell counts by 5 percent, CD34+ cell viability by 8.5 percent, and increased colony forming units (CFU) by 12.2 percent. Post-thaw CD34+ count/viability and CFU count are indicators of the potential for successful engraftment of the stem cells following transfusion in the patient, and it was clear that the optimized formulation of CryoStor was responsible for these post-preservation improvements in cell viability and function. Furthermore, using pre-formulated CryoStor will result in not only reduced labor time in lab processing but also higher processing efficiency overall."

BioLife Chief Executive Mike Rice commented: "Cryobanks' decision to adopt CryoStor as their standard cord blood biopreservative freezing media represents further confirmation of the value that our products bring to customers in the form of manufacturing and ingredient quality, measurably superior results, and ease of use. We're pleased to supply CryoStor to Cryobanks to support the growth of their business and will continue to expand our customer base and broaden adoption of CryoStor and HypoThermosol as the worldwide standard for media to transport, preserve and store cells, tissues, and organs."

About Cryobanks International:

Cryobanks International, Inc., located in Altamonte Springs, FL is a leader in the collection, processing, and banking of stem cells derived from umbilical cord blood. The stem cell rich cord blood (CB) is processed and stored using the company's proprietary processing methods and are stored for use in unrelated transplants. Cryobanks established the first and only nationwide public cord blood donation bank. The company also provides personal storage programs. In recent years, cord blood transplants (CBT's) have become widely recognized as a safe and effective alternative to traditional bone marrow transplants (BMT). Cryobanks International has processed over 16,000 cord blood units in its 13+ years of operation. The company is a National Marrow Donor Program Network Cord Blood bank, and is AABB accredited, FDA registered and cGMP/cGTP compliant. Cryobanks is also licensed by the States of New York, New Jersey and California for CB collection and/or processing. The company also provides consulting and management services for those interested in developing their own cord blood banking operations. For more information about Cryobanks International call 1-800-869-8608 or visit the website at

About BioLife Solutions, Inc:

BioLife Solutions develops and markets patented hypothermic storage/transport and cryopreservation media products for cells, tissues, and organs. The Company's proprietary HypoThermosol(R) and CryoStor(TM) platform of biopreservation media products are marketed to academic research institutions, hospitals, and commercial companies involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife products are serum-free and protein-free, fully defined, and formulated to reduce preservation-induced, delayed-onset cell damage and death. BioLife's enabling technology provides research and clinical organizations significant improvement in post-preservation cell and tissue and viability and function.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Media Relations: Investor Relations:

Len Hall Dan Matsui

Allen & Caron Inc. Allen & Caron Inc.

(949) 474-4300 (949) 474-4300

SOURCE BioLife Solutions, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. BioLife Solutions Expands Presence in Cell Therapy and Cord Blood Banking Market Segments
2. Expeditive Forms Strategic Alliance With Halcyon Search Solutions
3. Norm Botsford Joins Culbert Healthcare Solutions Strategic Services Team
4. SXC Health Solutions announces PBM services agreement with Health Plan of San Mateo
5. CareAnalyzer From DST Health Solutions Helps Health Plans Improve Care Management and Quality for Members
6. HighPoint Solutions Expands with New Chicago Office
7. Prasco to Distribute Generic Forms of Dorzolamide Hydrochloride-Timolol Maleate and Dorzolamide Hydrochloride Ophthalmic Solutions (Comparable to Mercks COSOPT(R) and TRUSOPT(R) Ophthalmic Solutions)
8. Wellsource Partners With Health Solutions Ltd. to Form Best-in-Class Health and Wellness Solutions for Its Clients.
9. Telehealth Solutions from American TeleCare, Inc. Support Heart Failure Management Study in Canada
10. Parrish Medical Center Deploys Clinical Xpert(TM) Solutions from Thomson Reuters
11. HireRight Named to Deloitte Technology Fast 50 for the Sixth Year in a Row : Attributes Customer Focus and Innovative Screening Solutions to its 230 Percent Revenue Growth
Post Your Comments:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
Breaking Medicine Technology: